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Summary 
HAVACS (HIV Atlanta VA Cohort Study) was initiated in 1982 in order to enhance 
clinical care and research for all HIV-positive veterans receiving care at the Atlanta VA 
Medical Center (AVAMC).  Every HIV-positive patient ever seen at the AVAMC has 
been included in HAVACS; to date over 4,268 patients have been entered into this 
cohort.  Prospective collection of data began in 1982 and includes a complete summary 
of the patient’s HIV history including any care they received before HAVACS.  The data 
are collected at each clinic visit and hospitalization in a prospective manner.  Cohort 
enrollment dates started in 1982 and are ongoing.  
 
Data are collected on patient demographics (gender, race, age, HIV risk group), HIV 
biomarkers (including CD4 cell count and viral load levels at date of diagnosis, nadir 
levels, date of threshold levels and current levels), antiretroviral regimens including time 
not on a regimen, start and stop dates, genotype data, data on HIV-related and AIDS-
defining conditions, other comorbid conditions, hepatitis B and hepatitis C virus testing, 
immunization status, dates of mortality or loss to follow-up and causes of death.  
 
  
Key Messages 
 Marked decrease in mortality since 1996 with the minority of deaths occurring in 
the hospital or being caused by AIDS-defining opportunistic infections since 
1996. Deaths due to end-stage renal disease and myocardial infarction were also 
uncommon with a stable incidence over the past 30 years. 
 In a population with a high rate of Hepatitis C (HCV) (32%), HCV is significantly 
associated with decreased survival time from date of AIDS diagnosis.  This trend 
is supported by evidence of a significant decrease in CD4 counts over the course 
of HIV-positive/HCV-positive compared to HIV-positive/HCV-negative patients.  
 When comparing patients followed in HAVACS to those followed by the 
Department of Defense, despite substantial differences in baseline 
characteristics and large differences in crude mortality rates, after controlling for 
important clinical and demographic variables, both 12-year survival and AIDS-
free survival rates were similar between the two study cohorts who have open 
access to care and medication.  
 Both protease inhibitors and non-nucleoside reverse transcriptase inhibitors were 
found to be associated with elevated apolipoproteins, specifically apoc-III.  In 
women, an additional association was found with elevated total cholesterol level 
that was not seen with the men while an elevation was seen in triglyceride levels 
for the men but not the women; these data add to the growing evidence of 
gender-related differences in the natural history, pharmacokinetics and toxicity of 
antiretroviral therapy. 
 Analysis of the continuum of care demonstrated a higher level of diagnosis, 
linkage to care, receipt of antiretrovirals and viral suppression than any U.S. 
cohort.    
  
Why was the cohort created?  
HAVACS (HIV Atlanta VA Cohort Study) was initiated in 1982 to enhance clinical care 
and research for all HIV-positive veterans seeking care at the Atlanta VA Medical 
Center. The HAVACS database provides health care providers with a summary of 
patient information while also being used for surveillance and research analyses. 
Moreover, it has been used to assess the feasibility of new studies and aids in the 
identification of patients eligible for approved research protocols. Essentially, it serves 
as an ongoing prospective, observational study for interdisciplinary HIV research in 
clinical, basic, epidemiological, biostatistical, and social sciences. Today, HAVACS is a 
powerful database utilized for the investigation of HIV-positive patients with respect to 
HIV and aging, non AIDS-related malignancies, hepatitis B and C co-infections, novel 
immunological markers for inflammation, and highly-active antiretroviral therapy 
(HAART) start time and drug sequencing. HAVACS has no independent funding; 
maintenance of data and reports are supported by a combination of research 
coordinators and clinicians. 
  
Who is in the cohort?  
This database includes all HIV-positive patients ever seen at the AVAMC. To date, 4268 
patients have been entered into this cohort and database. Prospective data collection 
began in 1982 and includes the full HIV history of patients including any care they 
received for their HIV disease before receiving care at the AVAMC.  
 
The patient population is 97.5% (n=4162) male, 71.6% (n=3054) African-
American/Black, 25.8% (n=1101) Caucasian/White and 1.6% Hispanic. Mean age is 52 
years. Men who have sex with men (MSM) represent the largest population [50.8% 
(n=2169)], followed by individuals with a history of injection drug use (IDU) which 
accounts for an additional 16.1% (n=687), and 4.4% (n=187) of individuals with high-risk 
heterosexual contact. Twenty-two percent of the patients were naïve to antiretrovirals at 
entry; 30.7% were naïve before starting HAART. Co-infection with hepatitis C is 
common with 21.9% of the cohort being dual infected, although the recent prevalence of 
HCV co-infection has decreased to 15.1% in current patients. Over 80% of our patients 
currently on therapy have undetectable viral loads. Since 1982, only 2.8% (n=120) of 
patients have been lost to follow-up (not seen in the last 24 months); 40.4% (n=1723) 
have died, 32.7% (n=1395) were seen in the 2014 calendar year, and 20.4% (n=869) 
have moved to other locations but remain in care. 
 
This cohort study was approved by the Emory IRB with a HIPAA waiver allowing entry 
and collection of data without requiring informed consent. Each study is separately 
approved by the Emory IRB. 
 
Characteristics of the entire HAVACS population as well as the current HAVACS 
population are shown in Table 1.   
How often have they been followed up?  
 
The Veterans Affairs (VA) population is unique in that these patients are likely to receive 
all treatment and care within the VA system. Since 1997, the data obtained through 
routine clinic visits have been supplemented with data from the VA Computerized 
Patient Record System (CPRS), an electronic system that houses all data for every 
patient seen in any hospital or clinic within the VA healthcare system allowing for the 
acquisition of data such as laboratory and non-ID clinic visits which would not have 
been available otherwise. 
 
Information is collected on patients seen in the AVAMC ID Clinic on standardized forms 
that include demographic characteristics, clinical symptoms, HIV-related diagnoses, 
prophylaxes, antiretroviral regimens, vaccinations, inpatient visits and diagnoses and 
laboratory measurements. Data are collected retrospectively for the entire clinical 
history of each patient if they were diagnosed elsewhere and prospectively once care is 
initiated at the AVAMC. Each inpatient and outpatient encounter is documented and the 
database is updated weekly for every patient contact with the AVAMC including 
inpatient and clinic visits as the patients are seen for routine clinical care or for research 
visits. Pharmaceutical data are also collected from the computerized pharmacy 
database. All data are kept in a secured and centralized database. If the patient has left 
care from the VA system, outcome data are collected from active sources such as 
family members and passive sources such as National Death Index and the National 
Veterans Benefits Database. The database is routinely checked for quality of data 
during analyses and routine use of the patient summary sheets.   
 For those patients who received healthcare from other providers before enrolling in the 
VA system, we attempt to determine the source of their HIV diagnosis. Over twenty-
seven percent were diagnosed at the AVAMC. This proportion has increased over the 
years, particularly since 2009 when routine testing became the model in the VA system.  
Twenty-three percent come from other VA locations, 21.6% are diagnosed outside of 
the VA system in private medical practices, 12.4% were diagnosed in the military, 4.1% 
were diagnosed in a health department or the county hospital, and 1.5% diagnosed in 
the prison system.  
 
The age distribution for HAVACS has changed dramatically over time. Almost 50% of 
our patients were between 30-39 years of age in 1986 compared to 10% in this age 
range in 2014 (Figure 1). In 1986, 88% of our patients were under 49 years of age.  
Today, 60% of our patients are over the age of 50 years. This significant shift to an 
older population in HAVACS is influenced by the dramatically improved survival now 
seen as well as a significant increase in those diagnosed over the age of 50.   
 
Trends in HIV and AIDS diagnoses have dramatically changed over the years in 
HAVACS (Figure 2). HIV diagnoses peaked in year 1989 with 250 new diagnoses.  
Since 1990-1992, the number of new diagnoses of HIV and AIDS cases declined before 
reaching the current steady state of 40 to 70 new cases each per year. The current 
trend of fewer patients diagnosed with AIDS is encouraging and likely represents the 
2009 policy change to test everyone seen in the VA system. HIV mortality has also 
changed substantially over the decades. In 1994, a quarter of patients in HAVACS died 
(rate of 25 deaths per 100 patients seen) (Figure 3). Just three years later, the rate 
dropped to 3 deaths/100 patients seen and has not been over a rate of 5/100 patients 
since. Much of this is correlated with the use of antiretroviral therapy in HAVACS. In 
1994, only 35% of the patients were receiving antiretrovirals (Figure 4). By 1997, this 
increased to 70% and is now at 88% of current patients. In 1996, 60% of HAVACS 
patients had viral load levels above 10,000 copies/mL and only 10% of the patients had 
a CD4 level above 500 cells/mm3 and 20% were below 50 cells/mm3 (Figures 5 and 6). 
In 2014, 55% of patients had a CD4 cell count >500 cells/mm3 and 60% were 
virologically suppressed.   
 
 
 
  
What has been measured?  
 
 
Phase Measurements 
Baseline 1982 and 
ongoing 
Demographic data 
 PCP prophylaxis data 
1990 Antiretroviral data including all dates of regimens 
 Genotype data 
 HCV, HBV data 
 VACS study data 
Ongoing Causes of mortality 
 
 
Types of Data collected:  
Clinical, laboratory and pharmaceutical data are collected for every patient. Laboratory 
data include CD4 cell count, HIV viral load, hepatitis serologies, G6PD, HLA B-5701, 
and vitamin D. In addition, immunization history including hepatitis, pneumococcal and 
TDaP vaccine status is obtained. Using the National VA HIV Clinical Case Registry 
(CCR), all patients in HAVACS are linked to ICD-9 morbidity data. The CCR is also 
used to generate important denominator data such as total number of patients seen on 
as inpatient or outpatient, and number on antiretrovirals. CD4 cell count and HIV viral 
load data, summaries of any laboratory test, medications and risk factor distribution can 
also be generated. These data allow the calculation of incidence for all parameters.  On 
an annual basis, patients not seen in over 24 months are evaluated for mortality by 
review of remote VA data, the VA national death index and the Social Security Death 
Index.  
 
 
Selected patients with vitamin D deficiency had DEXA studies done to assess bone 
density. Patients enrolled in the FRAM studies had targeted studies including CT scans, 
DEXA studies and anthropomorphic measurements. Patients enrolled in Veterans Aging 
Cohort Study (VACS) studies had phlebotomy for plasma and cells; in addition to other 
phlebotomy for selected sub-studies. 
 
 
 
 
  
What has it found? Key findings and publications 
 
Hepatitis C Coinfection Increases Mortality in HIV Infected Patients in the Pre and 
Post-HAART Era 
Although studies have consistently documented the negative impact of HIV coinfection 
on HCV disease, the effect of HCV coinfection on HIV disease is still unclear and even 
controversial.  A study in 1999 in HAVACS found no association between HCV-
positive/HIV-positive coinfection and progression to death in the pre-HAART era1.  We 
speculated that many factors, including the hepatotoxicity of HAART regimens and 
increased survival times for patients on HAART, might yield different findings and 
reexamined this association in the post-HAART era in 20042.  We found that:  1) In 
accordance with the previous HAVACS study, the prevalence of HCV coinfection was 
still high (31.6%).3 2) Coinfected patients were less likely to have received HAART than 
HCV- patients. 3) Coinfection with HCV results in significantly decreased survival from 
HIV and AIDS diagnoses. 4) Coinfection does not affect short or long-term CD4 cell 
count recovery with HAART.  
 
Association between antiretroviral therapy in men and women increased lipid 
levels 
In 2005 and 2006, we performed cross-sectional studies in both men and women to 
consider the association between antiretroviral therapy and increased lipid levels3,4.  We 
found both protease inhibitors and non-nucleoside reverse transcriptase inhibitors were 
associated with elevated apolipoproteins, specifically apoc-III.  In women, elevated total 
cholesterol level was also associated with therapy but this was not seen in men4.  
However, an elevation was seen in triglyceride levels for men but not women3.  These 
findings suggest impaired metabolism of triglyceride-rich lipoproteins and, in an older 
population with additional risk factors of smoking and diabetes, portend future 
atherosclerotic events in these patients. These data added to the growing evidence of 
gender-related differences in the natural history, pharmacokinetics and toxicity of 
antiretroviral therapy.    
 
Methicillin-resistant Staphylococcus aureus colonization in HIV-positive 
outpatients 
Data on the interaction between methicillin-resistant Staphylococcus aureus (MRSA) 
colonization and clinical infection are limited. During 2007-2008, we enrolled 600 
patients from HAVACS in a prospective cohort study 5-7.  MRSA colonization was 
detected in 15% of HIV-infected participants at baseline and 6 and 12 months; 41% in 
nares only, 21% in groin only, and 38% at both sites. Over a median of 2.1 years of 
follow-up, rate of infection was 2.5/100 person-years. Skin and soft tissue infections 
were the most common and 13% of these required hospitalization. Forty-eight percent 
of patients who developed a MRSA clinical infection had MRSA colonization at baseline 
compared with 6% of those where no infection developed (p<0.0001). In multivariate 
analysis, MRSA clinical infection was significantly associated with colonization of the 
groin (adjusted risk ratio (RRa) 4.8) and a history of MRSA infection (RRa 3.1). A 
suppressed HIV viral load and use of antiretroviral therapy were associated with a lower 
risk for development of MRSA clinical infection. MRSA prevention strategies that can 
effectively prevent or eliminate groin colonization are likely necessary to reduce clinical 
infections in this population. 
 
A Comparison of HAART Outcomes between the US Military HIV Natural History 
Study and HAVACS 
In 2013 we performed the first analysis comparing data from the US Military HIV Natural 
History Study (NHS) and HAVACS8.  We assessed the clinical outcomes for individuals 
with HIV from two very similar government-sponsored healthcare systems that reduced 
or eliminated many barriers associated with accessing treatment and care.  The 
combined total mortality rate was less than 10% for those diagnosed with HIV and 
initiating HAART since 1996.  The NHS patients were younger, started HAART at a 
higher CD4 cell count, and experienced less mortality than HAVACS patients.  Despite 
these substantial differences in baseline characteristics and large differences in crude 
mortality rates, 12-year survival and AIDS-free survival rates were similar between the 
two cohorts who have open access to care and medication after controlling for important 
clinical and demographic variables. These similarities existed despite dramatic 
differences in socioeconomic and behavioral characteristics.  Our analysis highlighted 
the need for comparisons of clinical outcomes in fee-for-care systems, as well as impact 
of early HIV screening.  Our data suggest that early screening, with subsequent higher 
CD4 cell count at diagnosis, will result in improved outcomes. 
 
Comparison of Colorectal Cancer Screening and Diagnoses in HIV-positive and 
HIV-negative Veterans 
In 2014 we examined the use of appropriate colorectal cancer (CRC) screening in HIV-
positive and HIV-negative veterans9. The results from this analysis suggest that patients 
are not properly being screened for CRC as roughly half of cases and their matched 
controls were not screened during the four year study period. At the time of the study, 
guidelines called for annual CRC screening for all 50 years and older. We found that 
cases had a significantly higher number of outpatient visits than their controls, resulting 
in more chances to be screened. The “first line” screening method of FOBT was utilized 
similarly in both populations (42.5% for cases vs. 41.4% for controls) though at a higher 
rate than in the non-VA population (38% national average screening rate) 10. Even with 
the limited number of diagnoses, differences were seen by race and age; 80% of HIV-
positive cases diagnosed with CRC during the study were black and two were less than 
50 years of age suggesting the need for larger studies to evaluate the need for earlier 
screening among HIV-positive and black individuals.  
 
Continuum of Care in HAVACS 
Also in 2014, the continuum of care in HAVACS was modeled in order to determine 
similarities and differences with national models11. Using a cross-sectional analysis of 
1,474 individuals who were currently receiving care in the ID clinic, we estimated that 
95.3% of individuals were diagnosed with HIV, 89.8% of individuals were linked to care, 
73.0% of individuals were retained in care, 65.9% of individuals were eligible for 
antiretroviral treatment (ART), 62.8% were prescribed ART, and 52.4% had a 
suppressed viral load (VL). Using an independent stage categorization, it was estimated 
that 83.9% of individuals were prescribed ART and 61.5% had a suppressed VL. These 
analyses showed that the HAVACS estimates were significantly better than national 
estimates at every stage. This may have reflected the benefits of a universal healthcare 
system. Since this publication, many similar analyses have opted to use independent 
stages for the continuum as this more accurately represents healthcare utilization. 
 
Contributions to VACS 
The Atlanta VA has been part of the NIH-funded Veterans Aging Cohort Study (VACS) 
since 2002. This longitudinal cohort study, comparing an HIV-positive population with an 
age, gender, race and site-matched HIV-negative population has addressed important 
comorbidities, influence of alcohol and drug abuse and prediction models for morbidity 
and mortality using the VACS Index. Overall, approximately 600 HIV-positive and 600 
HIV-negative veterans have enrolled in this study as part of the VACS-8 series of 
investigations. A description of VACS, questionnaire tools and a list of over 200 
publications produced from this study are available at www.va.cohort.org. 
 
Contributions to ART-CC 
In 2008, HAVACS joined 18 other cohorts in the established Antiretroviral Therapy 
Cohort (ART-CC).  This cohort was created to study the prognosis and mortality of HIV-
positive patients treated before the end of 200912.  Highlights of some of the work 
published by ART-CC with HAVACS are summarized here.   
 
In 2011, we compared the relative effectiveness of initial ART regimens estimated in 
AIDS Clinical Trial Group (ACTG) randomized controlled trials with that among patients 
receiving ART at ART-CC study sites13. We found the virologic and clinical efficacy 
observed in clinical trials were mirrored in the routine care setting at ART-CC clinical 
sites suggesting ART regimen performance in clinical trials likely translates to routine 
care settings. 
 
In 2012 we estimated the incidence of and risk factors for modifications to first ART 
regimen, treatment interruption and death in 21,801 patients from 18 cohorts in Europe 
and North America using competing-risks methods.14 Rates of modification and 
interruption were high, particularly in the first year of ART. During median 28 months 
follow-up, 40.3% patients modified their first ART. Rates of substitution and switches to 
nonstandard regimens were lower in 2006-2009 likely due to greater use of well 
tolerated once-daily drugs. 
 
In 2013, we published data on adult HIV-positive patients who started ART from 1998 
without a previous AIDS diagnosis from 17 cohorts in North America and Europe15. We 
examined between-cohort heterogeneity in crude and adjusted rates of AIDS and 
mortality using random-effects meta-analysis and meta-regression. Between-cohort 
variance in mortality rates was reduced from 0.84 to 0.24 (0.73 to 0.28 for AIDS rates) 
after adjustment for patient characteristics.  Heterogeneity between settings in 
outcomes of HIV treatment has implications for collaborative analyses, policy and 
clinical care.  
 In 2013, we published data on differences in all-cause mortality, as well as AIDS and 
non-AIDS death rates, among patients started on ART according to their geographical 
origin and ethnicity/race in Europe, Canada, and the United States between 1998 and 
200916. Migrants from sub-Saharan Africa (SSA) (AHR, 0.79; 95% confidence interval 
[CI], .68-.92) and Asia/West (AHR, 0.62; 95% CI, .41-.92) had lower mortality than 
Europeans; these differences appeared mainly attributable to lower non-AIDS mortality. 
Compared with white Canadians, mortality in Canadian First Nations people was 48% 
higher; both for AIDS and non-AIDS mortality rates and among US patients, when 
compared with whites, African Americans had higher AIDS and non-AIDS mortality. The 
lower mortality observed in migrants suggests "healthy migrant" effects, whereas the 
higher mortality in First Nations people and African Americans in North America 
suggests social inequality gaps. 
  
What are the main strengths and weaknesses? 
One of the main strengths of the study is that it represents a complete population cohort 
of all patients ever seen at the AVAMC with HIV with a long period of follow-up (mean 
82 months).  The AVAMC has the largest HIV-positive population in the VA system in 
the United States and offers very high rates of follow-up for routine record linkages. The 
VA population is unique in that these patients are likely to receive all treatment and care 
in the VA system.  Only 2.8% have been lost to follow-up since 1982.  Therefore, unlike 
many large clinical and research databases, loss to follow-up or missing clinical 
information is not a source of bias. 
 
One limitation of this cohort may be generalizability as the HAVACS cohort consists of 
veterans who are primarily black and male. This is not a product of lack of inclusion but 
rather a product of the low number of veterans in the US who are female and HIV-
positive. In addition, at the current time we do not have any stored biomedical 
specimens other than those used for specific studies.  
 
  
Can I get hold of the data? Where can I find out more?  
A subset of patients from HAVACS have been enrolled in VACS (n=500), SMART, 
OPTIMA, and FRAM 1 and 2.  Additionally, HAVACS is a member of the Antiretroviral 
Therapy Cohort Collaboration (ART-CC).  The studies using data from this cohort are 
funded through multiple grants and contracts including the CDC, the National Institute 
on Aging and The National Institute for Mental Health. 
 
HAVACS Cohort Contact:  
Dr. Jodie L. Guest is the Director of HIV Research at the Atlanta VA Medical Center and 
Professor at the Rollins School of Public Health and the School of Medicine, both at 
Emory University.  She can be reached at 1670 Clairmont Rd, Mailstop 111-RIM, 
Decatur, GA, 30033, USA, Jodie.Guest@emory.edu.   
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Table 1.  Demographic and selected characteristics of the HIV Atlanta VA 
Cohort Study, 1982-2014 
Covariate All patients (n=4268) Active patients (n=1533) 
Demographics 
 
 
Age at first visit 43.1 (21-82) 43.8 (21-82) 
Age at HIV diagnosis 36.0 (17-76) 36.0 (18-76) 
Male sex 97.5% (4162) 96.9% (1486) 
Race 
  
African-American/Black 71.6% (3054) 79.5% (1219) 
Caucasian/White 25.8% (1101) 18.0% (276) 
Hispanic 1.6% (67) 1.4% (22) 
Other or unknown 1.1% (46) 1.0% (16) 
Primary Risk Factor 
  
MSM 50.8% (2169) 55.4% (849) 
IVDU 16.1% (687) 8.5% (130) 
High Risk Heterosexual 4.4% (187) 6.1% (93) 
Unknown 23.2% (990) 26.0% (399) 
Other 5.5% (235) 4.0% (62) 
Referral 
  
Internal (AVAMC) 27.2% (1159) 23.2% (356) 
Other VAMC 23.0% (980) 16.8% (258) 
Private practice 21.6% (917) 27.3% (418) 
Military 12.4% (526) 15.9% (243) 
Other 15.8% (674) 16.8% (258) 
Current status 
  
Died 40.4% (1723) - 
Active 35.9% (1533) 100.0% (1533) 
Moved 20.4% (869) - 
Lost to follow-up 2.8% (120) - 
Other 0.54% (23) - 
Medical history 
  
HIV to Death (years) 7.5 (0-29.9) - 
AIDS diagnosis 66.5% (2839) 56.2% (926) 
Diagnosed by OI 50.3% (1428) 31.9% (295) 
Diagnosed by CD4 49.7% (1411) 68.1% (631) 
Hepatitis C- co-infection 21.9% (732) 15.1% (231) 
Chronic Hepatitis B co-infection 6.4% (274) 5.7% (87) 
MSM - men who have sex with men; IVDU - intraveneous drug user; OI - opportunistic infection 
 
 
 
  
Figure 1: Age Distribution by Year in HAVACS 
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Figure 2: Trends in HIV and AIDS Diagnoses by Year in HAVACS 
Trends in AIDS and HIV Disease at the VAMC
Year of Diagnosis
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Figure 3: HIV Mortality Rates by Year in HAVACS 
HIV Mortality at Atlanta VAMC
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Figure 4: Antiretroviral Therapy by Year in HAVACS 
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Figure 5: HIV RNA Results by Year in HAVACS 
HIV RNA Results at the VAMC
by Year
Patients on ARV
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Figure 6: CD4 Distribution by Year in HAVACS 
CD4 Distribution by Year
Patients on Therapy
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